{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:22:09Z","timestamp":1777951329982,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijgc.2025.102767","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:10:54Z","timestamp":1761930654000},"page":"102767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tailoring treatment for advanced and\/or recurrent ovarian cancer using the response of circulating tumor cells to therapy: a retrospective analysis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5174-0379","authenticated-orcid":false,"given":"Lyri","family":"Adar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-4321","authenticated-orcid":false,"given":"Eliya","family":"Shachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5061-0670","authenticated-orcid":false,"given":"Ido","family":"Laskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7987-404X","authenticated-orcid":false,"given":"Nadav","family":"Michaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0449-3057","authenticated-orcid":false,"given":"Adi","family":"Diner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilat","family":"Rotkop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galya","family":"Basol Kochav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ido","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-6426","authenticated-orcid":false,"given":"Tamar","family":"Safra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.102767_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102767_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1515\/cclm-2017-0019","article-title":"Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA","volume":"56","author":"Giannopoulou","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102767_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijgc.2025.102767_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","article-title":"New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination","volume":"175","author":"Coffman","year":"2016","journal-title":"Transl Res"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102767_bib5","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1159\/000492521","article-title":"Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker","volume":"48","author":"Zhang","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"24","key":"10.1016\/j.ijgc.2025.102767_bib6","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.3390\/cancers14246030","article-title":"The role of circulating tumor cells in ovarian cancer dissemination","volume":"14","author":"Szczerba","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102767_bib7","first-page":"3363","article-title":"The added value of circulating tumor cells examination in ovarian cancer staging","volume":"5","author":"Kolostova","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102767_bib8","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.molonc.2016.04.002","article-title":"Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel","volume":"10","author":"Blassl","year":"2016","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102767_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88780-w","article-title":"Clinical significance of circulating tumor cell related markers in patients with epithelial ovarian cancer before and after adjuvant chemotherapy","volume":"11","author":"Yousefi","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102767_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005615","article-title":"Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation","volume":"10","author":"Pantel","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102767_bib11","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3390\/cancers15072185","article-title":"Detection and molecular characterization of circulating tumour cells: challenges for the clinical setting","volume":"15","author":"Strati","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102767_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10585-024-10267-5","article-title":"Clinical applications of circulating tumor cells in patients with solid tumors","volume":"41","author":"Smit","year":"2024","journal-title":"Clin Exp Metastasis"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102767_bib13","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.3390\/ijms21134813","article-title":"A pilot study of the predictive potential of chemosensitivity and gene expression assays using circulating tumour cells from patients with recurrent ovarian cancer","volume":"21","author":"Guadagni","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102767_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000583","article-title":"Community-driven development of a modified progression-free survival ratio for precision oncology","volume":"4","author":"Mock","year":"2019","journal-title":"ESMO Open"},{"issue":"33","key":"10.1016\/j.ijgc.2025.102767_bib15","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2018 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102767_bib16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102767_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/annonc\/mdn544","article-title":"Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience","volume":"20","author":"Olmos","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102767_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1593\/tlo.12247","article-title":"Interpretation of changes in circulating tumor cell counts","volume":"5","author":"Coumans","year":"2012","journal-title":"Transl Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102767_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.eururo.2016.07.051","article-title":"Circulating tumor cells in a Phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer","volume":"71","author":"Vogelzang","year":"2017","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102767_bib20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41416-018-0245-0","article-title":"Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?","volume":"119","author":"Watson","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102767_bib21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s12094-020-02446-z","article-title":"Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?","volume":"23","author":"Gallego","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ijgc.2025.102767_bib22","article-title":"The progression-free survival ratio as outcome measure in recurrent ovarian carcinoma patients: current and future perspectives","volume":"42","author":"van de Kruis","year":"2022","journal-title":"Gynecol Oncol Rep"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102767_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-high risk breast cancer patients","volume":"106","author":"Rack","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102767_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12890-019-1029-x","article-title":"Circulating tumor cells before initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review","volume":"19","author":"Jiang","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102767_bib25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.molonc.2013.02.013","article-title":"Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer","volume":"7","author":"Smerage","year":"2013","journal-title":"Mol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102767_bib26","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/cas.15255","article-title":"Prognostic impact of circulating tumor cells detected with the microfluidic \u201cuniversal CTC-chip\u201d for primary lung cancer","volume":"113","author":"Kanayama","year":"2022","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102767_bib27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/annonc\/mdm558","article-title":"Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications","volume":"19","author":"Nol\u00e9","year":"2008","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ijgc.2025.102767_bib28","article-title":"Comparison of comprehensive genomic profiling (CGP) and hotspot next generation sequencing (NGS) assays in identifying treatment options for care of patients with metastatic cancer in in the community setting","volume":"34","author":"Alvarez","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102767_bib29","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1158\/0008-5472.CAN-15-3043","article-title":"Cancer therapy directed by comprehensive genomic profiling: a single center study","volume":"76","author":"Wheler","year":"2016","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102767_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2006.03.035","article-title":"Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer","volume":"103","author":"Spizzo","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102767_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/IGC.0b013e3181a8331f","article-title":"Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent\/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy","volume":"19","author":"Bellone","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102767_bib32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/medicina60060915","article-title":"The role of epithelial cell adhesion molecule cancer stem cell marker in evaluation of hepatocellular carcinoma","volume":"60","author":"El-Kholy","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102767_bib33","first-page":"349","article-title":"The role of EpCAM in physiology and pathology of the epithelium","volume":"31","author":"Martowicz","year":"2016","journal-title":"Histol Histopathol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102767_bib34","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.102767_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/OTT.S278092","article-title":"PARP inhibitor applicability: detailed assays for homologous recombination repair pathway components","volume":"15","author":"O\u2019Sullivan Coyne","year":"2022","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijgc.2025.102767_bib36","series-title":"Private Health Insurance: History, Politics and Performance European Observatory on Health Systems and Policies","first-page":"264","article-title":"Integrating public and private insurance in the Israeli health system: an attempt to reconcile conflicting values","author":"Brammli-Greenberg","year":"2020"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25018894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25018894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:37:47Z","timestamp":1777887467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25018894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1048891X25018894"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102767","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring treatment for advanced and\/or recurrent ovarian cancer using the response of circulating tumor cells to therapy: a retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102767","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102767"}}